CADTH

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

HUMAN INSULIN (Entuzity KwikPen)

(Eli Lilly Canada Inc.)

Indication: To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

July 22, 2021

Disclaimer: The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

CADTH

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0672
Name of the drug and Indication(s)	Human insulin (Entuzity KwikPen) To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Organization Providing Feedback	FWG

1. Recommendation revisions Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	**Major revisions:** A change in recommendation **category** or patient **population** is requested	☐
	Minor revisions: A change in reimbursement **conditions** is requested	☐
No Request for Reconsideration	**Editorial revisions:** Clarifications in recommendation **text** are requested	X
	No requested revisions	☐

2. Change in recommendation category or conditions Complete this section if major or minor revisions are requested

3. Clarity of the recommendation Complete this section if editorial revisions are requested for the following elements
a) Recommendation rationale
b) Reimbursement conditions and related reasons
For the initiation criteria, could CDEC/CADTH clarify if the 200 units of insulin per day is specific to insulin R, or rather any insulin product? “Patients with diabetes mellitus with unacceptable glycemic control who require more than 200 units of insulin per day, with or without other therapies.” In the discussion section, could CADTH clarify if the comparative products are only U200 and U300 formulations or any insulin? “CDEC noted that the submitted price of U500-R is lower than the publicly available list prices of brand-name insulin analogues, including those of U200 and U300 formulations.”

c) Implementation guidance